#novatocalifornia

NOVATO, Calif., July 13, 2026 /PRNewswire/ -- Lighthouse Pharmaceuticals today announced new analyses from the Phase 2/3 GAIN trial demonstrating that atuzaginstat, a gingipain inhibitor targeting Porphyromonas gingivalis (Pg), was associated with ...

The $100,000 Linda G. O'Bryant Prize will recognize bold new research frameworks investigating Unidentified Anomalous Phenomena (UAP) at the intersection of consciousness and physics. NOVATO, Calif., July 8, 2026 /PRNewswire-PRWeb/ -- The Institute ...